Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2022 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
January 10, 2022 08:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
January 03, 2022 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
December 20, 2021 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics,...
November 18, 2021 08:30 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical...
November 09, 2021 16:30 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
November 08, 2021 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Reports Third Quarter 2021 Financial Results

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug...
November 03, 2021 08:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces CEO Transition

STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
November 01, 2021 16:15 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
October 04, 2021 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...